- Business - Oct 25 SLAC, Stanford launch ‘Bits & Watts’
- Careers - Oct 25 Opinion: What men would do to fix the workplace equality gap
- Business - Oct 25 Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
- Medicine - Oct 25 Fragranced products: risks for people and profits?
- Business - Oct 24 Double win for spin- offs of TUM
- Administration - Oct 24 Millions at stake in crucial treasury negotiations
- Business - Oct 21 Behaviour incentives raise GCSE attainment in schools in poor neighbourhoods
- Administration - Oct 20 U-M annual research funding rises to $1.39 billion
- Business - Oct 20 Four years later, what effect has expanded video gambling had on Illinois?
- Business - Oct 19 Berkeley economists launch Opportunity Lab
- Environment - Oct 19 MIT to neutralize 17 percent of carbon emissions through purchase of solar energy
- Business - Oct 19 Housing market drives franchise expansion
- Environment - Oct 19 3 Questions: Maria Zuber on stepping up MIT’s response to climate change
- Business - Oct 18 La Follette School’s Smeeding, others offer proposal for reducing child poverty in U.S
- Medicine - Oct 18 Making a splash in health care economics
- Environment - Oct 17 How to reach ecologically sustainable welfare societies
Effective link between diabetes researches and business sector
The Lund University Diabetes centre has been conducting cutting-edge research on diabetes for a number of years. however, this has not been matched by corresponding success on the commercial side. Not a lot has happened – until now, when the centre has its own innovation expert as part of a new programme from the Lund University Innovation System, LUIS.
The expert is Sylvie Bove, who has long experience from the pharmaceutical industry. She sees herself as a link between the business sector and the researchers - an intermediary who can speak both parties’ language.
She has invested a lot of time in getting to know the diabetes researchers and understanding their way of thinking.
“In order to achieve results, I must be able to make suggestions that suit them”, she says.
From her previous experience of university researchers and doctors, she expected to meet quite a lot of scepticism, but was pleasantly surprised.
“With my business background, I’m out of place in the research environment. Nevertheless I have been met with openness, curiosity and a surprising amount of interest”, she says.
Sylvie Bove has succeeded in starting four concrete projects in the six months she has worked at LUDC, the Lund University Diabetes Centre.
Two of the projects involve new companies under the University’s holding company, LU Bio, while the other two are cooperation projects with the pharmaceutical giant Novo Nordisk.
She has also arranged a meeting for large and small companies in the pharmaceutical and biotechnology industries, at which LU’s leading diabetes researchers presented their work.
“The business representatives were impressed to meet a research group that was actively looking to cooperate with them. They had never come across that in Sweden before”, explains Sylvie Bove.
She thinks the time is right for this type of cooperation. The pharmaceutical industry, which has had increasing difficulty finding new big sellers, has realised that it needs help with the early stages of the research. At the same time, the universities are becoming more and more interested in opening the doors to their laboratories and offices.
Sylvie Bove therefore has a lot of plans for the future; she is going to organise innovation seminars, produce a brochure about the diabetes centre aimed at businesses, and develop a ‘quick reference guide’ with points for researchers to remember when they sign agreements with companies.
Sylvie Bove’s post is being financed for three years by Tillväxtverket (the Swedish Agency for Economic and Regional Growth) and the Lund University Innovation System as part of the “Innovation Officer” programme.
The programme has its origins in the question of why the University’s strong research environments have not led to corresponding strength in the area of innovation and can be regarded as an offer from LUIS to the strong research groups at the University.
For this reason, Sylvie Bove will also be contacting the cancer researchers in CREATE Health and the BioCARE network to see what skills they need for business development.
“I think there are a lot of possibilities for commercialisation of products and tech- niques in the field of cancer as well”, she says.
Text: Ingela Björck
Last job offers
- Business/Economics - 24.10
Research Project Manager (80-100%)
- Business/Economics - 14.10
Wissenschaftliche(r) Mitarbeiter(in) / Doktorand(in)
- Medicine/Pharmacology - 4.10
Professeur-e ordinaire ou associé-e et médecin-chef-fe du service d’obstétrique
- Medicine/Pharmacology - 15.9
Leiter/in Forschung & Entwicklung Pflege (Professorenstelle)
- Medicine/Pharmacology - 15.9
Leiter/in des Studiengangs Master of Science in Pflege
- Medicine/Pharmacology - 25.10
Postdoctoral position in early onset adolescent psychosis study
- Business/Economics - 25.10
Professor in Japanese (PER 2016/80)
- Medicine/Pharmacology - 20.10
UniversitätsassistentIn - Postdoc